摘要
目的探讨依洛尤单抗治疗高脂血症合并高血压的疗效及对凝血功能、血管内皮功能的影响。方法选择2019年1月-2020年12月于本院治疗并确诊为高脂血症合并高血压患者80例作为研究对象,随机分为观察组和对照组两组,每组各40例。观察组患者实施常规西药联合依洛尤单抗注射液治疗,对照组患者实施常规西药治疗。两组患者连续治疗12周,比较两组患者的临床疗效、血压和血脂水平、凝血指标、血小板活化功能指标、血管内皮功能和不良反应发生情况。结果观察组患者治疗总有效率(85.0%)明显高于对照组的(52.50%),差异有统计学意义(P<0.05);治疗后,两组患者收缩压和舒张压水平均显著低于治疗前,且观察组患者收缩压和舒张压水平均低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平较治疗前降低,高密度脂蛋白胆固醇(HDL-C)水平较治疗前升高,且观察组患者TC、TG、LDL-C水平显著低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);治疗后,两组患者凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血酶时间(APTT)较治疗前减少,纤维蛋白原(FIB)水平较治疗前升高,且观察组患者TT、PT、APTT显著少于对照组,FIB水平高于对照组,差异有统计学意义(P<0.05);治疗后,两组患者血小板膜糖蛋白P选择素(CD62P)水平和溶酶体膜蛋白(CD63)水平均显著低于治疗前,且观察组患者血小板膜糖蛋白CD62P水平和溶酶体膜蛋白CD63水平均低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者血管假性血友病因子(vWF)显著低于治疗前,血浆一氧化氮(NO)显著高于治疗前,且观察组患者vWF低于对照组,血浆一氧化氮显著高于对照组,差异有统计学意义(P<0.05);两组患者总不良反应发生率比较,差异无统计学意义(P>0.05)。结论依洛尤单抗治疗高�
Objective To explore the curative effect of evolocumab in the treatment of hyperlipidemia combined with hypertension and its influence on blood coagulation function and vascular endothelial function.Methods 80 patients diagnosed with hyperlipidemia complicated with hypertension those were admitted to our hospital from January 2019 to December 2020 were selected as the research objects,and they were randomly divided into an observation group and a control group,with 40 cases in each group.The observation group was treated with conventional western medicine combined with evolocumab injection,and the control group was treated with conventional western medicine only.The two groups were treated continuously for 12 weeks.The clinical efficacy,blood pressure and blood lipids,coagulation indexes,platelet activation function indexes,vascular endothelial function and occurrence of adverse reactions were compared between the two groups of patients.Results Compared with the control group,the observation group had a significantly higher total effective rate of treatment(85.0%vs.52.50%,P<0.05).After treatment,the levels of systemic blood pressure(SBP),diastolic blood pressure(DBP)were significantly decreased in both two groups,and the SBP and DBP in the observation group were lower than those in the control group(P<0.05).After treatment,levels of total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C)were significantly decreased in both two groups,and the content of high-density lipoprotein cholesterol(HDL-C)level was significantly increased;and levels of TC、TG、and LDL-C in the observation group were lower than those in the control group,while the level of HDL-C was higher than that of control group(P<0.05).After treatment,thrombin time(TC),prothrombin time(PT)and partial thrombin time(APTT)were significantly were significantly decreased,and the fibrinogen(FIB)level was significantly increased;levels of TT、PT、and APTT of the observation group were lower than those in the control group,level o
作者
闫记生
胡法国
李朝亮
Yan Jisheng;Hu Faguo;Li Zhaoliang(Department of cardiovascular medicine,Zhengzhou seventh people's hospital,Zhengzhou,Henan,450000,China)
出处
《齐齐哈尔医学院学报》
2022年第7期618-622,共5页
Journal of Qiqihar Medical University
关键词
依洛尤单抗
高脂血症
高血压
凝血功能
血管内皮功能
Evolocumab
Hyperlipidemia
Hypertension
Coagulation
Vascular endothelial function
